Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation
Top Cited Papers
- 25 October 2012
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 367 (17), 1587-1595
- https://doi.org/10.1056/nejmoa1113566
Abstract
There are limited data comparing radiofrequency catheter ablation with antiarrhythmic drug therapy as first-line treatment in patients with paroxysmal atrial fibrillation. We randomly assigned 294 patients with paroxysmal atrial fibrillation and no history of antiarrhythmic drug use to an initial treatment strategy of either radiofrequency catheter ablation (146 patients) or therapy with class IC or class III antiarrhythmic agents (148 patients). Follow-up included 7-day Holter-monitor recording at 3, 6, 12, 18, and 24 months. Primary end points were the cumulative and per-visit burden of atrial fibrillation (i.e., percentage of time in atrial fibrillation on Holter-monitor recordings). Analyses were performed on an intention-to-treat basis. There was no significant difference between the ablation and drug-therapy groups in the cumulative burden of atrial fibrillation (90th percentile of arrhythmia burden, 13% and 19%, respectively; P=0.10) or the burden at 3, 6, 12, or 18 months. At 24 months, the burden of atrial fibrillation was significantly lower in the ablation group than in the drug-therapy group (90th percentile, 9% vs. 18%; P=0.007), and more patients in the ablation group were free from any atrial fibrillation (85% vs. 71%, P=0.004) and from symptomatic atrial fibrillation (93% vs. 84%, P=0.01). One death in the ablation group was due to a procedure-related stroke; there were three cases of cardiac tamponade in the ablation group. In the drug-therapy group, 54 patients (36%) underwent supplementary ablation. In comparing radiofrequency ablation with antiarrhythmic drug therapy as first-line treatment in patients with paroxysmal atrial fibrillation, we found no significant difference between the treatment groups in the cumulative burden of atrial fibrillation over a period of 2 years. (Funded by the Danish Heart Foundation and others; MANTRA-PAF ClinicalTrials.gov number, NCT00133211.)Keywords
This publication has 25 references indexed in Scilit:
- 2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial FibrillationCirculation, 2011
- Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: Rate and Rhythm ManagementCanadian Journal of Cardiology, 2011
- Electropathological Substrate of Long-Standing Persistent Atrial Fibrillation in Patients With Structural Heart DiseaseCirculation: Arrhythmia and Electrophysiology, 2010
- Electropathological Substrate of Longstanding Persistent Atrial Fibrillation in Patients With Structural Heart DiseaseCirculation, 2010
- Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)European Heart Journal, 2010
- Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial FibrillationJAMA, 2010
- Treatment of Atrial Fibrillation With Antiarrhythmic Drugs or Radiofrequency AblationCirculation: Arrhythmia and Electrophysiology, 2009
- Catheter Ablation Versus Antiarrhythmic Drugs for Atrial FibrillationCell Metabolism, 2008
- A Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Paroxysmal Atrial FibrillationJournal of the American College of Cardiology, 2006
- Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study)†European Heart Journal, 2005